Hassan Faaiq, Thomson Luke Thomas Middleton, Toor Gurpal, Alfahad Qusay
Department of Ophthalmology, South Warwickshire NHS foundation trust, Warwick CV34 5BW, United Kingdom.
Int J Ophthalmol. 2019 Sep 18;12(9):1503-1506. doi: 10.18240/ijo.2019.09.21. eCollection 2019.
Our aim was to report quality of life (QOL) outcomes following Xen45 Gel Stent implantation surgery in patients suffering with primary open angle glaucoma (POAG). A retrospective analysis was performed on all patients who had Xen45 implantation surgery during a 2-year period (Jun, 2016-Apr, 2018). Of 52 consecutive patients were included with a total of 58 eyes being operated on. QOL was compared both pre-operatively and 6 weeks post-operatively using the GQL-15 questionnaire. There was an overall improvement in GQL-15 summary scores for our patient group. All item scores showed either no change or some degree of improvement. The Xen45 Gel Stent Implant is a promising new intervention which has shown improved QOL scores in our patient group. Further, higher power studies are now needed to compare the Xen45 to trabeculectomy (TE), which is currently the gold standard.
我们的目的是报告原发性开角型青光眼（POAG）患者接受Xen45凝胶支架植入手术后的生活质量（QOL）结果。对在2年期间（2016年6月至2018年4月）接受Xen45植入手术的所有患者进行了回顾性分析。纳入了连续52例患者，共58只眼睛接受了手术。使用GQL-15问卷在术前和术后6周对生活质量进行了比较。我们患者组的GQL-15总结评分总体有所改善。所有项目评分要么没有变化，要么有一定程度的改善。Xen45凝胶支架植入是一种有前景的新干预措施，在我们的患者组中显示出生活质量评分有所提高。此外，现在需要进行更高效能的研究，将Xen45与目前的金标准小梁切除术（TE）进行比较。
